RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Decitabine Conditioning Improves Natural Killer Cell Maturation and Limits CD8(+) T Cell Terminal Differentiation Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients.
Decitabine Conditioning Improves Natural Killer Cell Maturation and Limits CD8(+) T Cell Terminal Differentiation Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
异基因干细胞移植(alloSCT)可通过移植物抗肿瘤免疫反应治愈急性髓系白血病(AML)患者。然而,alloSCT后复发仍是主要临床挑战,这凸显了辅助治疗的必要性,既要在alloSCT前降低肿瘤负荷,又要在移植后增强自然杀伤(NK)细胞和T细胞免疫。低甲基化药物地西他滨(DAC)具有良好的耐受性,并对白血病细胞具有直接抗增殖和促凋亡作用,因此具有前景。
此外,DAC可调节肿瘤免疫原性并表现出免疫调节特性。然而,目前缺乏关于在alloSCT前预处理方案中加入DAC对移植后NK和T细胞免疫表型及功能影响的整体认识。
在此,我们研究了在alloSCT前预处理方案中加入DAC对AML患者移植后NK和T细胞格局及功能的免疫调节效应。这项回顾性队列研究纳入了接受alloSCT的AML患者,其预处理方案中包含DAC(n = 30)或不包含DAC(n = 22)。在alloSCT后3个月和6个月采集外周血样本。采用高维流式细胞术评估表型特征,同时进行增殖、细胞因子产生和细胞毒性试验以研究其功能。无论预处理方案如何,NK细胞上的检查点分子,包括PD-1、TIM-3、LIGHT和OX40,在alloSCT后均处于低水平。
值得注意的是,含DAC预处理显著增加了共表达KIRah、KIRb、CD69、CD57和DNAM-1的成熟NK细胞簇的丰度。
值得注意的是,来自DAC预处理患者的NK细胞保留了其细胞毒性和细胞因子产生能力,其中成熟NK细胞对K562刺激的反应性显著高于未成熟NK细胞。在CD4+ T细胞中,DAC预处理降低了TH1/TH17细胞的频率以及一部分TH17细胞的比例。有趣的是,DAC治疗导致共表达免疫检查点分子(包括PD-1、TIGIT、KLRG1、TIM-3和CD57)的CD8+ T细胞簇丰度降低,提示其终末分化表型减少。在功能上,来自DAC预处理患者的CD4+和CD8+ T细胞在抗CD3刺激下表现出强劲的增殖能力,并展现出多功能性,产生IFN-、TNF-和IL-2。
值得注意的是,非DAC预处理患者中共表达抑制性检查点分子的CD8 T细胞丰度较高与多克隆刺激下IL-2产生呈负相关。总体而言,在AML患者allo-SCT后,将DAC加入预处理方案与对NK细胞和T细胞有利的免疫调节效应相关。这些发现表明,DAC可能增强供者NK和T细胞介导的移植物抗肿瘤反应,支持其作为allo-SCT前辅助治疗的进一步临床评估。2025 American Society for Blood and Marrow Transplantation。由Elsevier Inc.出版。保留所有权利。
Allogeneic stem cell transplantation (alloSCT) can be curative for acute myeloid leukemia (AML) patients due to graft-versus-tumor immune responses.
However, relapse post-alloSCT remains a major clinical challenge, underscoring the necessity for adjuvant treatments that both reduce tumor load before alloSCT and strengthen natural killer (NK) cell and T cell immunity post-transplantation. The hypomethylating agent decitabine (DAC) holds promise as it is well-tolerated and has direct antiproliferative and proapoptotic effects on leukemic cells.
In addition, DAC modulates tumor immunogenicity and exhibits immunomodulatory properties. Yet integral insight into the impact of adding DAC to the pre-alloSCT conditioning on the immunophenotype and function of NK and T cells post-alloSCT is lacking.
Here we investigated the immunomodulatory effects of adding DAC to the pre-alloSCT conditioning on the NK and T cell landscape and function in AML patients post-transplantation. This retrospective cohort study included AML patients who underwent alloSCT with DAC (n = 30) or without DAC (n = 22) as part of their conditioning regimen.
Peripheral blood samples were collected at 3 months and 6 months post-alloSCT. High-dimensional flow cytometry was used to assess the phenotypic profiles, whereas proliferation, cytokine production, and cytotoxicity assays were performed to study their function. Irrespective of the conditioning regimen, checkpoint molecules on NK cells, including PD-1, TIM-3, LIGHT, and OX40, were low post-alloSCT.
Notably, DAC conditioning significantly increased the abundance of mature NK cell clusters coexpressing KIRah, KIRb, CD69, CD57, and DNAM-1. Interestingly, NK cells from DAC-conditioned patients retained their cytotoxic and cytokine production capacity, with mature NK cells demonstrating significantly enhanced responsiveness to K562 stimulation compared to immature NK cells. Within the CD4 + T cells, DAC conditioning reduced the frequencies of T H1 /T H17 cells and a proportion of T H17 cells.
Interestingly, DAC treatment led to a diminished abundance of CD8 + T cell clusters coexpressing immune checkpoint molecules, including PD-1, TIGIT, KLRG1, TIM-3, and CD57, implying a less terminally differentiated phenotype. Functionally, CD4 + and CD8 + T cells from DAC-conditioned patients demonstrated robust proliferation in response to anti-CD3 stimulation and exhibited polyfunctionality, producing IFN- , TNF- , and IL-2.
Notably, the higher abundance of CD8 T cells co-expressing inhibitory checkpoint molecules in non-DAC-conditioned patients was inversely associated with IL-2 production on polyclonal stimulation.
Overall, the addition of DAC to the conditioning regimen was associated with favorable immunomodulatory effects on NK cells and T cells post-alloSCT in AML patients.
These findings suggest that DAC may enhance donor NK and T cell-mediated graft-versus-tumor responses, supporting its further clinical evaluation as an adjuvant prior to alloSCT. 2025 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
MEMBER ACCOUNT
登录成功会直接打开下一页。